Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03255720
Other study ID # diffusion tensor imaging
Secondary ID
Status Not yet recruiting
Phase N/A
First received August 15, 2017
Last updated September 23, 2017
Start date September 29, 2017
Est. completion date December 31, 2022

Study information

Verified date September 2017
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Diffusion Tensor imaging of white matter degeneration in Alzheimer disease


Description:

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, accountings for 60-70% of all demented cases. It is a neuro-pathological diagnosis determined by presence of neurofibrillary tangles and senile plaques in the brain of patients with dementia. The disease frequently starts with memory impairment, but is invariably followed by a progressive global cognitive impairment. The major risk factor for Alzheimer disease is age, with prevalence doubling every 5 years after the age of 65.

Diagnosis of Alzheimer's typically involves physical and neurological exams, as medical history and mental status evaluation, laboratory investigations and it involves brain imaging (such as MRI) which could identify other causes of problems such as stroke, tumor or head trauma. By physical and neurological examination, Alzheimer's disease characterized by gradual onset and progressive decline in cognition with sparring of motor and sensory function until later stages; the average course of Alzheimer's disease is approximately a decade, with a range of 3 to 20 years duration from diagnosis to death .Memory impairment is present in the earliest stages of the disease; patients have difficulty learning new information and retaining it for more than few minutes. As the disease advances, the ability to learn increasingly compromised, more distant memories are lost. Other cognitive loses include aphasia, apraxia, disorientation and impaired judgment. Cognitive impairment affects daily life; patients have difficulty planning meals, managing finances or medication, using telephone, driving. Many capacities may remain intact until later stages including performance of self-care activities of daily living as eating, bathing. Patients evidence personality alteration, irritability, anxiety, depression. Delusion, hallucination and aggression. Laboratory Evaluation includes Biochemical markers as measurement of Cerebrospinal fluid including Tau protein, amyloid beta peptides or neural thread protein and measurement of urinary biomarkers including neural thread protein. Also testing including Apo lipoprotein E epsilon 4 allele presenilin genes, amyloid precursor gene or TREM2. Diffusion tensor imaging (DTI) is an imaging technology based on magnetic resonance diffusion weighted imaging, which can make quantitative analysis of anisotropy of water molecules in different directions, so as to observe the microstructure of tissues non-invasively. So Diffusion tensor imaging can provide information of fiber orientation, the injury of fiber, and membrane permeability which cannot be obtained from conventional MRI. Diffusion tensor imaging enables mapping of White matter microstructure changes in development, aging and neurological disorders, From the tensor, it's possible to derive the mean diffusivity (DM) and the fractional anisotropy (FA) which is the most robust measures of anisotropy which measure the degree of deviation from isotropic diffusion. ). More recently, an additional DT-MRI derived index has been proposed .This index measures the degree of similarity of orientation of neighboring voxels and its named inter-voxel coherence (C).

So Diffusion tensor imaging has therefore become a powerful technique in the study of neurodegenerative diseases in recent years.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 31, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria:

1. cognitive complaints with interference in complex occupational and social activities.

2. changes in cognition reported by the patient ,informant or clinician.

3. absence of profound sub-cortical ischemic changes.

Exclusion Criteria:

1. state of delirium

2. stroke event within 2 weeks

3. appearance of cortical and /cortico-subcortical non -lacunar territorial infarcts and watershed infarcts ,hemorrhage ,signs of normal pressure hydrocephalus ,and specific causes of white matter lesions (e.g. multiple sclerosis, sarcoidosis, brain irradiation)

4. derangements in serology tests contributing to cognitive impairment (e.g. abnormal levels of free T4 or rapid plasma reagin.

5. severe hearing or visual impairment.

6. cases of severe dementia.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease. provide a complete picture of the distribution of microstructural white matter damage in Alzheimer's disease 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A
Withdrawn NCT05497817 - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Terminated NCT03132272 - Immunoadsorption for Treatment of Alzheimer's Disease N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02267486 - Exploratory Study for the Validity of QuQu Scale N/A
Active, not recruiting NCT03748303 - Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Phase 1
Completed NCT03611439 - Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients N/A
Completed NCT04058886 - Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers N/A
Recruiting NCT03584568 - Reappraising Intergeneration Relationships in Dementia Caregiving N/A
Not yet recruiting NCT05113732 - Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Completed NCT03811847 - A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Phase 4
Terminated NCT03044249 - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression Phase 2
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Completed NCT03718494 - Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
Completed NCT03602391 - The Senior Companion Program Plus N/A
Completed NCT03548584 - A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Recruiting NCT02951559 - SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Phase 4